SLNO
Price
$67.47
Change
-$4.69 (-6.50%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
3.31B
39 days until earnings call
SYRE
Price
$12.77
Change
-$1.22 (-8.72%)
Updated
Apr 4, 04:59 PM (EDT)
Capitalization
933.38M
34 days until earnings call
Ad is loading...

SLNO vs SYRE

Header iconSLNO vs SYRE Comparison
Open Charts SLNO vs SYREBanner chart's image
Soleno Therapeutics
Price$67.47
Change-$4.69 (-6.50%)
Volume$21.17K
Capitalization3.31B
Spyre Therapeutics
Price$12.77
Change-$1.22 (-8.72%)
Volume$34.41K
Capitalization933.38M
SLNO vs SYRE Comparison Chart
Loading...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SLNO vs. SYRE commentary
Apr 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SLNO is a StrongBuy and SYRE is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 05, 2025
Stock price -- (SLNO: $72.16 vs. SYRE: $13.99)
Brand notoriety: SLNO and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SLNO: 112% vs. SYRE: 147%
Market capitalization -- SLNO: $3.31B vs. SYRE: $933.38M
SLNO [@Biotechnology] is valued at $3.31B. SYRE’s [@Biotechnology] market capitalization is $933.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SLNO’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • SLNO’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SLNO is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SLNO’s TA Score shows that 6 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • SLNO’s TA Score: 6 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SLNO is a better buy in the short-term than SYRE.

Price Growth

SLNO (@Biotechnology) experienced а +7.08% price change this week, while SYRE (@Biotechnology) price change was -20.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.73%. For the same industry, the average monthly price growth was -16.65%, and the average quarterly price growth was -18.36%.

Reported Earning Dates

SLNO is expected to report earnings on May 13, 2025.

SYRE is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-10.73% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLNO($3.31B) has a higher market cap than SYRE($933M). SLNO YTD gains are higher at: 60.534 vs. SYRE (-39.906). SLNO has higher annual earnings (EBITDA): -173.63M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. SLNO (291M). SYRE has less debt than SLNO: SYRE (0) vs SLNO (52.8M). SLNO (0) and SYRE (0) have equivalent revenues.
SLNOSYRESLNO / SYRE
Capitalization3.31B933M355%
EBITDA-173.63M-208.57M83%
Gain YTD60.534-39.906-152%
P/E RatioN/A1.72-
Revenue00-
Total Cash291M603M48%
Total Debt52.8M0-
FUNDAMENTALS RATINGS
SLNO vs SYRE: Fundamental Ratings
SLNO
SYRE
OUTLOOK RATING
1..100
273
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
57100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3590
P/E GROWTH RATING
1..100
10075
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SYRE's Valuation (77) in the Pharmaceuticals Major industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that SYRE’s stock grew similarly to SLNO’s over the last 12 months.

SLNO's Profit vs Risk Rating (57) in the Medical Specialties industry is somewhat better than the same rating for SYRE (100) in the Pharmaceuticals Major industry. This means that SLNO’s stock grew somewhat faster than SYRE’s over the last 12 months.

SLNO's SMR Rating (98) in the Medical Specialties industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that SLNO’s stock grew similarly to SYRE’s over the last 12 months.

SLNO's Price Growth Rating (35) in the Medical Specialties industry is somewhat better than the same rating for SYRE (90) in the Pharmaceuticals Major industry. This means that SLNO’s stock grew somewhat faster than SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (75) in the Pharmaceuticals Major industry is in the same range as SLNO (100) in the Medical Specialties industry. This means that SYRE’s stock grew similarly to SLNO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SLNOSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 8 days ago
86%
Bullish Trend 8 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
SLNO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMIEX14.27N/A
N/A
MM S&P 500® Index Svc
RRCOX55.42N/A
N/A
T. Rowe Price U.S. Equity Research R
IJMAX15.15N/A
N/A
VY® JPMorgan Mid Cap Value A
HWSCX51.47N/A
N/A
Hotchkis & Wiley Small Cap Value C
IICHX10.80N/A
N/A
AMF Large Cap Equity H

SLNO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLNO has been loosely correlated with BRNS. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SLNO jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLNO
1D Price
Change %
SLNO100%
-2.05%
BRNS - SLNO
56%
Loosely correlated
N/A
KANT - SLNO
45%
Loosely correlated
-3.88%
ACLX - SLNO
40%
Loosely correlated
-7.12%
NKTX - SLNO
40%
Loosely correlated
-10.73%
GRCE - SLNO
38%
Loosely correlated
-4.76%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with APGE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then APGE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-9.68%
APGE - SYRE
48%
Loosely correlated
-7.51%
IMNM - SYRE
48%
Loosely correlated
-7.00%
BEAM - SYRE
48%
Loosely correlated
-10.93%
CGON - SYRE
46%
Loosely correlated
-15.74%
PRME - SYRE
46%
Loosely correlated
-10.06%
More